Ads
related to: rituximab for ms patients- Insightful Discussions
Tune In To Hear Experts Discuss
Hot Topics In Clinical Care.
- Digital Education Library
Stream Education In RMS.
Education At Your Fingertips.
- Partners In Care
Discover RMS Content
Featuring National Experts.
- Voice Of The Patient
Hear From RMS Patients About
Their Treatment Experiences.
- Watch RMS Expert Videos
Hear From Specialists About
Key Topics In Relapsing MS.
- Educational Materials
Download Brochures & Newsletters
For Your Practice On Demand.
- Insightful Discussions
Search results
Results From The WOW.Com Content Network
Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. [18] It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in children and adults, but not recommended in elderly patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura ...
Cross elucidated that Rituximab is an effective treatment for MS in humans through modulation of B cells, though the exact mechanisms are still to be determined. [12] To determine what the optimal response to rituximab therapy is, Cross looked at the tissue biomarkers of patients with multiple sclerosis on rituximab therapy. [13]
Over 50% of MS patients may use complementary and alternative medicine, although numbers vary greatly depending on the definition of alternative medicine used. [205] In the United States, it is estimated that 75% of the MS patient populations use at least one complementary and alternative medicine for treatment and symptomatic control.
A small, short-duration clinical trial [103] with MS patients was conducted at the University of California, San Francisco. In October 2007 data was presented at the European Congress of MS in Prague regarding safety findings of a pilot study of low dose naltrexone therapy in multiple sclerosis by neurological researchers in Milan, Italy. [104]
multiple sclerosis, chronic lymphocytic leukemia Ulocuplumab [55] mab: human: CXCR4 (CD184) hematologic malignancies Urelumab [16] mab: human: 4-1BB (CD137) cancer etc. Urtoxazumab [9] mab: humanized: Escherichia coli: diarrhoea caused by E. coli: Ustekinumab [49] Stelara: mab: human: IL-12, IL-23: Y: multiple sclerosis, psoriasis, psoriatic ...
Stephen L. Hauser is a professor of the Department of Neurology at the University of California, San Francisco (UCSF) specializing in immune mechanisms and multiple sclerosis (MS). He has contributed to the establishment of consortia that have identified more than 50 gene variants that contribute to MS risk.
Ads
related to: rituximab for ms patients